Previous 10 | Next 10 |
Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the upcoming oral presentation of data from the dose-escala...
SAN FRANCISCO , CA / ACCESSWIRE / October 23, 2020 / Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. FULT Investo...
Homology Medicines ([[FIXX]] +3.5%) has announced a new in vivo gene therapy development program for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome.Development candidate HMI-203 is a potential one-time AAVHSC treatment designed to deliver functional copi...
HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers Program Expands Homology’s CNS P...
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit o Fireside Chat: S...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...
Homology Medicines (NASDAQ: FIXX ) : Q2 GAAP EPS of -$0.78 misses by $0.02 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key Data Successfully Executed Multiple Internal 2,000-Liter Bioreactor Runs Using Comme...
- Executive with Extensive Rare Disease Expertise in Global Finance and Commercial Operations - BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Boar...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...